A beginning in science. A longer ambition in investment.
Wytham Lane is being built around the belief that some of the most worthwhile investment opportunities are found in difficult science, where the technical question is important, the evidence takes work, and the route to commercial use needs careful capital. We begin with longevity and regenerative medicine because that is where the founder’s training and experience are deepest.
A note from the founder
I began my career in laboratory science, working on stem cells and cardiovascular biology. At Oxford I spent years studying human heart cells and asking how their function could be understood, measured and potentially changed. Those experiments gave me a practical appreciation for what regenerative medicine might achieve. They also showed me how far a result in the lab can be from a treatment that works in patients.
Later, in biotech equity research and venture investing, I found myself asking a different set of questions about the same science. What actually needs to be proved? How much capital will it take? What happens when an experiment disappoints? And who is going to build the company through that difficult middle part?
The more time I spent on both sides, the less interested I became in attractive labels. I’m interested in useful science, the judgment to recognise its limitations, and the people who can take it forward.
Wytham Lane starts with that work. My ambition is to build an investment institution that can continue to follow important technical advances over time, without losing the care and discipline required to make good decisions in the first place.
Dr. Faizzan Syed AhmadFounder, Wytham Lane
Science, investing and company development.
Dr. Faizzan Syed Ahmad’s path to Wytham Lane began at the laboratory bench in New York. He started as a research assistant in Professor David A. Sassoon’s laboratory at Mount Sinai School of Medicine, and went on to the New York Stem Cell Foundation Research Institute, where he became a Senior Research Associate and directed its induced pluripotent stem cell core.
That work took him to Doha, where he was a Senior Research Associate at Weill Cornell Medicine-Qatar and a scientist with Qatar Foundation at the Qatar Cardiovascular Research Center and Sidra Medicine. Those years brought his stem cell training into cardiovascular research, which became the centre of his doctoral work.
He completed a DPhil in cardiovascular pharmacology and stem cell biology at the University of Oxford, training under Professor Sir Magdi Yacoub, Professor Ming Lei and Professor Derek A. Terrar. His doctorate was supported by Qatar Foundation, through a special exemption from Her Highness Sheikha Moza, and by the Prof. Sir Magdi Yacoub Fellowship from the Magdi Yacoub Foundation and the Magdi Yacoub Institute. At Oxford he made human heart cells from induced pluripotent stem cells and studied how they function, research that led to US Patent 12,590,294, granted in March 2026, on which he is a named inventor for a process that produces mature atrial cardiomyocytes.
From the laboratory he moved into investing, first in biotechnology equity research at H.C. Wainwright, where he covered cell and gene therapy, and then as Investment Director at Cambrian BioPharma. There he evaluated and helped finance therapeutic companies from seed through Series B, held board roles at Vita Therapeutics and Telos Biotechnology, served on the Investment Committee and helped incubate a number of new companies.
Today he is a co-founder of Kinara Bio, an Oxford University Innovation spin-out built on PAK1 allosteric activation, and serves as Strategic Advisor, Healthcare, at MBK Holding in Qatar. Wytham Lane is his effort to bring these experiences together into a focused, long-term investment institution, one that treats scientific evidence, capital and the work of building companies as parts of the same undertaking.
Three kinds of experience
- Science
- Human stem-cell and cardiovascular biology; translational research; the limits of preclinical models.
- Investment
- Biotech equity research, venture diligence, financing milestones, ownership and investment risk.
- Building
- Evaluating scientific spinouts, teams, routes to clinical proof and company formation.
A reminder to observe patiently.
The name reflects a personal connection to Oxford and an appreciation for the long-running research at Wytham Woods. It is intended as a reminder that good decisions begin with patient observation and a willingness to follow the evidence over time, rather than with certainty about what the future must look like.
A degree from the University of Oxford does not imply the University’s endorsement of Wytham Lane, and Wytham Lane is independent of the University.
We are starting with an area we understand and building toward something that can accommodate more. We will measure that ambition by the quality of the work, not by the size of the claims we make about it.